Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01780545 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT01780545: Completed Phase 2 study, sponsored by Noah Hahn, M.D..
NCT01780545 is a Phase 2 study that has completed, run by Noah Hahn, M.D.. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01780545, a Phase 2 study, has completed, sponsored by Noah Hahn, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel can prolong survival time compared to docetaxel alone in participants with locally advanced or metastatic urothelial carcinoma (UC) that are relapsed or refractory after receiving a platinum-containing regimen.
Primary Outcome
To determine whether docetaxel administered in combination with OGX-427 provides a survival benefit compared to docetaxel alone.
Interventions
- DRUG Docetaxel
- DRUG OGX-427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
What the finished NCT01780545 record still lists
NCT01780545 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01780545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01780545 about?
NCT01780545 is a clinical study titled "Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer". This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel can prolong survival time compared to docetaxel alone in participants ...
What is the current status of trial NCT01780545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2013-04. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01780545?
The interventions under investigation include: Docetaxel (DRUG), OGX-427 (DRUG).
Who is sponsoring clinical trial NCT01780545?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01780545's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia